108258-54-4

Basic information

• Product Name: METHYL 2,3-DICHLOROBENZOATE
• Synonyms: methyl 2,3-dichloroquinoxaline-6-carboxylate;2,3-dichloro-6-Quinoxalinecarboxylic acid methyl ester
• CAS NO: 108258-54-4
• Molecular Formula: C₁₀H₆Cl₂N₂O₂
• Molecular Weight: 205
• Mol File: 108258-54-4.mol
• Article Data: 6

Chemical Properties

• Melting Point: 117～119℃
• Appearance: /
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• CAS DataBase Reference: METHYL 2,3-DICHLOROBENZOATE(CAS DataBase Reference)
• NIST Chemistry Reference: METHYL 2,3-DICHLOROBENZOATE(108258-54-4)
• EPA Substance Registry System: METHYL 2,3-DICHLOROBENZOATE(108258-54-4)

Safety Data

• Hazardous Substances Data: 108258-54-4(Hazardous Substances Data)

Usage

General Description

Methyl 2,3-dichlorobenzoate is a chemical compound with the molecular formula C8H6Cl2O2. It is a clear, colorless to pale yellow liquid with a slightly sweet odor. METHYL 2,3-DICHLOROBENZOATE is commonly used as an intermediate in the production of pharmaceuticals, agrochemicals, and other organic compounds. It is also used as a solvent and in the manufacturing of fragrance and flavoring agents. Methyl 2,3-dichlorobenzoate is considered to have low toxicity, but it should be handled with care and proper safety measures should be taken when working with it.

Upstream product

• 354793-04-7 2,3-dioxo-1,2,3,4-tetrahydro-quinoxaline-6-carboxylic acid methyl ester 
• 36692-49-6 Methyl 3,4-diaminobenzoate 

Relevant articles and documents

Synthesis and Fungicidal Activity of 1,4-Dithiino[2,3-b]quinoxaline-2,3-dicarbonitriles

A series of eleven 1,4-dithiino[2,3-b]quinoxaline-2,3-dicarbonitriles was prepared by reaction of 2,3-dichloroquinoxalines with disodium (Z)-2,3-dimercapto-2-butenedinitrile in N,N-dimethylformamide. These products were tested for in-vitro fungicidal activity by a Minimum Inhibitory Concentration (MIC) method. Several of these compounds showed broad-spectrum fungicidal activity. The activity exhibited by these compounds was greatly dependent upon the substituents of the quinoxaline ring, with the nitro-substituted derivatives showing the higest levels of antifungal activity. None of the compounds prepared, however, showed fungicidal activity comparable to that of the commercial fungicides screened.

Novel [1,2,4]Triazolo[4,3-a]Quinoxaline Derivative, Method For Preparing Same, And Pharmaceutical Composition For Preventing Or Treating BET Protein-Related Diseases, Containing Same As Active Ingredient

Provided are a novel [1,2,4]triazolo[4,3-a]quinoxaline derivative, a method for preparing the same, and a pharmaceutical composition for preventing or treating bromodomain extra-terminal (BET) protein-related diseases including cancer and autoimmune disea

FUSED TRICYCLIC COMPOUNDS WITH ADENOSINE A2a RECEPTOR ANTAGONIST ACTIVITY

The present invention relates to certain certain fused tricyclic heteroaryl rings compounds of the Formula (I) (also referred to herein as the "Fused Tricyclic Compounds"), wherein M, Q, U, W, X, Y, Z, R1, R2, and R3, and rings C and D are as herein described. The present invention also provides compositions comprising at least one Fused Tricyclic Compound, and use of such compounds in the treatment of central nervous system diseases or disorders such as Parkinson's disease.